Russell Investments Group Ltd. Has $429,000 Stock Position in Theravance Biopharma, Inc. $TBPH

Key Points

• Russell Investments Group Ltd. increased its stake in Theravance Biopharma, Inc. by 118.5% in Q1, holding 48,059 shares valued at approximately $429,000.
• The stock trading at $13.88 has a market cap of $699 million and an average rating of Strong Buy from analysts, with a consensus price target of $21.33.
• Insider Rhonda Farnum sold 10,000 shares for $113,900, reducing her ownership by nearly 3% to 326,918 shares.

Russell Investments Group Ltd. boosted its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 118.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 48,059 shares of the biopharmaceutical company's stock after purchasing an additional 26,069 shares during the period. Russell Investments Group Ltd. owned about 0.10% of Theravance Biopharma worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in TBPH. Nuveen LLC bought a new position in Theravance Biopharma in the first quarter valued at $3,348,000. Newtyn Management LLC lifted its stake in Theravance Biopharma by 5.7% in the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after acquiring an additional 258,337 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares during the last quarter. Millennium Management LLC lifted its stake in Theravance Biopharma by 71.1% in the fourth quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company's stock valued at $1,815,000 after acquiring an additional 80,140 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Theravance Biopharma by 3.5% in the first quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company's stock valued at $18,579,000 after acquiring an additional 69,919 shares during the last quarter. Institutional investors own 99.10% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research note on Tuesday, June 17th. Zacks Research upgraded shares of Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research note on Friday, August 15th. Finally, BTIG Research raised their target price on shares of Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Strong Buy" and a consensus price target of $21.33.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the sale, the senior vice president owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.90% of the stock is owned by corporate insiders.

Theravance Biopharma Stock Up 0.7%

Shares of NASDAQ:TBPH traded up $0.10 during midday trading on Friday, hitting $14.15. The stock had a trading volume of 66,273 shares, compared to its average volume of 284,532. The company's 50-day moving average price is $12.06 and its 200-day moving average price is $10.41. The company has a market capitalization of $712.54 million, a P/E ratio of 58.75 and a beta of 0.05. Theravance Biopharma, Inc. has a fifty-two week low of $7.88 and a fifty-two week high of $14.55.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.